266 related articles for article (PubMed ID: 10602515)
1. Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.
DeCristofaro MF; Betz BL; Wang W; Weissman BE
Oncogene; 1999 Dec; 18(52):7559-65. PubMed ID: 10602515
[TBL] [Abstract][Full Text] [Related]
2. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.
Uno K; Takita J; Yokomori K; Tanaka Y; Ohta S; Shimada H; Gilles FH; Sugita K; Abe S; Sako M; Hashizume K; Hayashi Y
Genes Chromosomes Cancer; 2002 May; 34(1):33-41. PubMed ID: 11921280
[TBL] [Abstract][Full Text] [Related]
3. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB.
Betz BL; Strobeck MW; Reisman DN; Knudsen ES; Weissman BE
Oncogene; 2002 Aug; 21(34):5193-203. PubMed ID: 12149641
[TBL] [Abstract][Full Text] [Related]
4. Rhabdoid tumor predisposition syndrome.
Sredni ST; Tomita T
Pediatr Dev Pathol; 2015; 18(1):49-58. PubMed ID: 25494491
[TBL] [Abstract][Full Text] [Related]
5. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.
Biegel JA; Tan L; Zhang F; Wainwright L; Russo P; Rorke LB
Clin Cancer Res; 2002 Nov; 8(11):3461-7. PubMed ID: 12429635
[TBL] [Abstract][Full Text] [Related]
7. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression.
Hasselblatt M; Gesk S; Oyen F; Rossi S; Viscardi E; Giangaspero F; Giannini C; Judkins AR; Frühwald MC; Obser T; Schneppenheim R; Siebert R; Paulus W
Am J Surg Pathol; 2011 Jun; 35(6):933-5. PubMed ID: 21566516
[TBL] [Abstract][Full Text] [Related]
8. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations.
Sévenet N; Lellouch-Tubiana A; Schofield D; Hoang-Xuan K; Gessler M; Birnbaum D; Jeanpierre C; Jouvet A; Delattre O
Hum Mol Genet; 1999 Dec; 8(13):2359-68. PubMed ID: 10556283
[TBL] [Abstract][Full Text] [Related]
9. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
10. No evidence for hypermethylation of the hSNF5/INI1 promoter in pediatric rhabdoid tumors.
Zhang F; Tan L; Wainwright LM; Bartolomei MS; Biegel JA
Genes Chromosomes Cancer; 2002 Aug; 34(4):398-405. PubMed ID: 12112529
[TBL] [Abstract][Full Text] [Related]
11. Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Kohashi K; Izumi T; Oda Y; Yamamoto H; Tamiya S; Taguchi T; Iwamoto Y; Hasegawa T; Tsuneyoshi M
Hum Pathol; 2009 Mar; 40(3):349-55. PubMed ID: 18973917
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies.
Decristofaro MF; Betz BL; Rorie CJ; Reisman DN; Wang W; Weissman BE
J Cell Physiol; 2001 Jan; 186(1):136-45. PubMed ID: 11147808
[TBL] [Abstract][Full Text] [Related]
13. hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
Rousseau-Merck MF; Versteege I; Legrand I; Couturier J; Mairal A; Delattre O; Aurias A
Cancer Res; 1999 Jul; 59(13):3152-6. PubMed ID: 10397258
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors.
Hoot AC; Russo P; Judkins AR; Perlman EJ; Biegel JA
Am J Surg Pathol; 2004 Nov; 28(11):1485-91. PubMed ID: 15489652
[TBL] [Abstract][Full Text] [Related]
15. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
Caramel J; Medjkane S; Quignon F; Delattre O
Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
17. Rhabdoid tumors: clinical approaches and molecular targets for innovative therapy.
Kerl K; Holsten T; Frühwald MC
Pediatr Hematol Oncol; 2013 Oct; 30(7):587-604. PubMed ID: 23848359
[TBL] [Abstract][Full Text] [Related]
18. hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities.
Bourdeaut F; Fréneaux P; Thuille B; Lellouch-Tubiana A; Nicolas A; Couturier J; Pierron G; Sainte-Rose C; Bergeron C; Bouvier R; Rialland X; Laurence V; Michon J; Sastre-Garau X; Delattre O
J Pathol; 2007 Feb; 211(3):323-30. PubMed ID: 17152049
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressor hSNF5/INI1 modulates cell growth and actin cytoskeleton organization.
Medjkane S; Novikov E; Versteege I; Delattre O
Cancer Res; 2004 May; 64(10):3406-13. PubMed ID: 15150092
[TBL] [Abstract][Full Text] [Related]
20. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
